Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020

被引:3
|
作者
Chen, Kun [1 ]
Jiang, Kehua [2 ]
Tang, Lannan [2 ]
Chen, Xiaolong [2 ]
Hu, Jianxin [2 ]
Sun, Fa [2 ]
机构
[1] Guizhou Prov Peoples Hosp, NHC Key Lab Pulm Immune Related Dis, Guiyang, Peoples R China
[2] Guizhou Prov Peoples Hosp, Dept Urol, Guiyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
drug trials; prostate cancer; chemotherapy; gene-targeted; immunotherapy; IMMUNE-CHECKPOINT INHIBITORS; RADIOTHERAPY; STATISTICS;
D O I
10.3389/fonc.2021.647110
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The overall aging of the world population has contributed to the continuous upward trend in the incidence of prostate cancer (PC). Trials on PC therapy have been extensively performed, but no study has analyzed the overall trends and characteristics of these trials, especially for those carried out in China. This study aimed to provide insights on the future direction of drug development in PC, thus supplying essential supportive data for stakeholders, including researchers, patients, investors, clinicians, and pharmaceutical industry. The details of the clinical trials of drug therapies for PC during January 1, 2010, to January 1, 2020, were collected from Pharmaprojects. A total of 463 clinical trials on different therapies with 132 different drugs were completed. The long-acting endocrine therapy with few side effects, radiotherapy combined with immune checkpoint inhibitors, gene-targeted chemotherapeutics, and novel immunotherapeutic products changed the concept of PC treatment. In mainland China, 31 trials with 19 drugs have been completed in the 10 assessment years. China has initiated a few trials investigating a limited number of drug targets, centered in a markedly uneven geographical distribution of leading clinical trial units; hence, the development of PC drugs has a long way to go. Given the large patient pool, China deserves widespread attention for PC drug research and development. These findings might have a significant impact on scientific research and industrial investment.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Trend of drug clinical trials in mainland China from 2009 to 2020
    Cao, Yu
    Liao, Lianming
    Liu, Xin
    Zheng, Qingshan
    Xu, Zhongyuan
    Niu, Haitao
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (09) : 1499 - 1507
  • [2] The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020
    Zhong, Qiaofeng
    Tao, Yunxia
    Chen, Haizhu
    Zhou, Yu
    Huang, Liling
    Han, Xiaohong
    Shi, Yuankai
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2021, 11
  • [3] Pediatric Clinical Trials in Mainland China Over the Past Decade (From 2009 to 2020)
    Wu, Wen-Wen
    Ji, Xing
    Wang, Hao
    Chen, Feng
    Ding, Qian
    Zhang, Guan-dong
    Li, Man
    Wang, Shan-shan
    Ni, Ming-ming
    Liu, Qing-qing
    Xu, Jing
    Wang, Qian
    FRONTIERS IN MEDICINE, 2021, 8
  • [4] Racial Distribution of Participants in Nonmelanoma Skin Cancer Clinical Trials From 2010 to 2020
    Nickles, Melissa A.
    Tsoukas, Maria M.
    DERMATOLOGIC SURGERY, 2021, 47 (09) : 1278 - 1281
  • [5] Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer
    Zhou, Wenhao
    Zhang, Wei
    Yan, Shi
    Zhang, Kaixuan
    Wu, Han
    Chen, Hongyu
    Shi, Minfeng
    Zhou, Tie
    CANCERS, 2024, 16 (03)
  • [6] Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries
    Aurélie De Bruycker
    Phuoc T. Tran
    Ariel H. Achtman
    Piet Ost
    World Journal of Urology, 2021, 39 : 317 - 326
  • [7] Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries
    De Bruycker, Aurelie
    Tran, Phuoc T.
    Achtman, Ariel H.
    Ost, Piet
    WORLD JOURNAL OF UROLOGY, 2021, 39 (02) : 317 - 326
  • [8] Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
    Olson, William C.
    Heston, Warren D. W.
    Rajasekaran, Ayyappan K.
    REVIEWS ON RECENT CLINICAL TRIALS, 2007, 2 (03) : 182 - 190
  • [9] Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies
    Morris, MJ
    Scher, HI
    SURGICAL ONCOLOGY-OXFORD, 2002, 11 (1-2): : 13 - 23
  • [10] Characteristic analysis of clinical trials for new traditional Chinese medicines in mainland China from 2013 to 2021
    Zhou, Yinghong
    Yang, Juan
    He, Yingchun
    Lv, Yinghua
    Wang, Chunli
    Deng, Hongyong
    Huang, Jihan
    FRONTIERS IN MEDICINE, 2022, 9